|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TACC1 |
Gene summary for TACC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TACC1 | Gene ID | 6867 |
| Gene name | transforming acidic coiled-coil containing protein 1 | |
| Gene Alias | Ga55 | |
| Cytomap | 8p11.22 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O75410 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6867 | TACC1 | LN22 | Human | Oral cavity | OSCC | 3.24e-09 | 1.33e+00 | 0.1733 |
| 6867 | TACC1 | LP15 | Human | Oral cavity | LP | 1.21e-02 | 9.78e-01 | 0.2174 |
| 6867 | TACC1 | EOLP-1 | Human | Oral cavity | EOLP | 3.87e-14 | 3.58e-01 | -0.0202 |
| 6867 | TACC1 | EOLP-2 | Human | Oral cavity | EOLP | 2.94e-04 | 2.34e-01 | -0.0203 |
| 6867 | TACC1 | NEOLP-1 | Human | Oral cavity | NEOLP | 6.72e-08 | 4.15e-01 | -0.0194 |
| 6867 | TACC1 | NEOLP-2 | Human | Oral cavity | NEOLP | 2.53e-10 | 2.78e-01 | -0.0196 |
| 6867 | TACC1 | NEOLP-3 | Human | Oral cavity | NEOLP | 3.26e-16 | 3.46e-01 | -0.0191 |
| 6867 | TACC1 | SYSMH1 | Human | Oral cavity | OSCC | 3.10e-13 | -3.63e-01 | 0.1127 |
| 6867 | TACC1 | SYSMH3 | Human | Oral cavity | OSCC | 8.08e-05 | 4.63e-01 | 0.2442 |
| 6867 | TACC1 | SYSMH4 | Human | Oral cavity | OSCC | 7.36e-14 | -5.03e-01 | 0.1226 |
| 6867 | TACC1 | SYSMH5 | Human | Oral cavity | OSCC | 1.10e-13 | -5.20e-01 | 0.0647 |
| 6867 | TACC1 | SYSMH6 | Human | Oral cavity | OSCC | 6.71e-05 | -5.09e-01 | 0.1275 |
| 6867 | TACC1 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 4.88e-04 | 2.49e-01 | -0.2126 |
| 6867 | TACC1 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 5.00e-07 | 7.65e-01 | -0.2247 |
| 6867 | TACC1 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 4.03e-04 | 5.57e-01 | -0.2027 |
| 6867 | TACC1 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 7.42e-09 | 5.02e-01 | -0.1833 |
| 6867 | TACC1 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 4.32e-03 | 2.60e-01 | -0.23 |
| 6867 | TACC1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 2.97e-07 | 4.24e-01 | -0.23 |
| 6867 | TACC1 | 047563_1562-all-cells | Human | Prostate | BPH | 3.50e-14 | 4.24e-01 | 0.0791 |
| 6867 | TACC1 | 052095_1628-all-cells | Human | Prostate | BPH | 3.11e-11 | 3.67e-01 | 0.1032 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007051 | Colorectum | AD | spindle organization | 58/3918 | 184/18723 | 4.71e-04 | 5.20e-03 | 58 |
| GO:1902850 | Colorectum | AD | microtubule cytoskeleton organization involved in mitosis | 48/3918 | 147/18723 | 5.87e-04 | 6.21e-03 | 48 |
| GO:0007052 | Colorectum | AD | mitotic spindle organization | 40/3918 | 120/18723 | 1.03e-03 | 9.61e-03 | 40 |
| GO:00070511 | Colorectum | MSS | spindle organization | 53/3467 | 184/18723 | 4.23e-04 | 5.19e-03 | 53 |
| GO:19028501 | Colorectum | MSS | microtubule cytoskeleton organization involved in mitosis | 44/3467 | 147/18723 | 5.17e-04 | 5.98e-03 | 44 |
| GO:00070521 | Colorectum | MSS | mitotic spindle organization | 36/3467 | 120/18723 | 1.52e-03 | 1.39e-02 | 36 |
| GO:00070512 | Colorectum | FAP | spindle organization | 41/2622 | 184/18723 | 1.50e-03 | 1.34e-02 | 41 |
| GO:0021987 | Colorectum | FAP | cerebral cortex development | 28/2622 | 114/18723 | 1.80e-03 | 1.55e-02 | 28 |
| GO:0021543 | Colorectum | FAP | pallium development | 36/2622 | 169/18723 | 6.06e-03 | 3.81e-02 | 36 |
| GO:0030900 | Colorectum | FAP | forebrain development | 70/2622 | 379/18723 | 8.64e-03 | 4.98e-02 | 70 |
| GO:00309001 | Colorectum | CRC | forebrain development | 66/2078 | 379/18723 | 1.36e-04 | 2.57e-03 | 66 |
| GO:00219871 | Colorectum | CRC | cerebral cortex development | 24/2078 | 114/18723 | 1.45e-03 | 1.57e-02 | 24 |
| GO:00215431 | Colorectum | CRC | pallium development | 32/2078 | 169/18723 | 1.74e-03 | 1.79e-02 | 32 |
| GO:0021537 | Colorectum | CRC | telencephalon development | 43/2078 | 248/18723 | 2.01e-03 | 2.01e-02 | 43 |
| GO:00070513 | Colorectum | CRC | spindle organization | 32/2078 | 184/18723 | 6.70e-03 | 4.77e-02 | 32 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:00215436 | Esophagus | ESCC | pallium development | 94/8552 | 169/18723 | 5.79e-03 | 2.14e-02 | 94 |
| GO:00070522 | Liver | Cirrhotic | mitotic spindle organization | 46/4634 | 120/18723 | 6.56e-04 | 4.98e-03 | 46 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TACC1 | SNV | Missense_Mutation | c.886G>T | p.Gly296Cys | p.G296C | O75410 | protein_coding | tolerated(0.06) | possibly_damaging(0.59) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| TACC1 | SNV | Missense_Mutation | rs779300910 | c.488N>T | p.Ser163Leu | p.S163L | O75410 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TACC1 | SNV | Missense_Mutation | rs758999833 | c.1640N>T | p.Ala547Val | p.A547V | O75410 | protein_coding | tolerated(0.22) | benign(0.091) | TCGA-AN-A0XP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TACC1 | SNV | Missense_Mutation | c.1084N>A | p.Ala362Thr | p.A362T | O75410 | protein_coding | tolerated(0.28) | benign(0.015) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TACC1 | SNV | Missense_Mutation | rs778594616 | c.1895N>A | p.Arg632Gln | p.R632Q | O75410 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| TACC1 | insertion | In_Frame_Ins | novel | c.1619_1620insATATCTGTATGGAGT | p.Pro540_Val541insTyrLeuTyrGlyVal | p.P540_V541insYLYGV | O75410 | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| TACC1 | SNV | Missense_Mutation | novel | c.1340N>G | p.His447Arg | p.H447R | O75410 | protein_coding | tolerated(0.38) | benign(0.055) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TACC1 | SNV | Missense_Mutation | rs377342873 | c.938N>T | p.Ser313Leu | p.S313L | O75410 | protein_coding | tolerated(0.09) | benign(0.037) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TACC1 | SNV | Missense_Mutation | c.1484N>C | p.Asp495Ala | p.D495A | O75410 | protein_coding | tolerated(0.07) | benign(0.043) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TACC1 | SNV | Missense_Mutation | c.824C>G | p.Thr275Arg | p.T275R | O75410 | protein_coding | tolerated(0.4) | benign(0.133) | TCGA-Q1-A6DW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |